Low NDRG2 Expression Predicts Poor Prognosis in Solid Tumors: A Meta-analysis of Cohort Study

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2020 Oct 8

PMID 33031336

Citations 3

Authors

Aiqin Gu

Jie Xu

Jun Ye

Chuanmeng Zhang

Affiliations

Soon will be listed here.

Abstract

Background: As a member of the N-myc down-regulated gene family, N-Myc downstream-regulated gene 2 (NDRG2) contributes to the tumorigenesis of various types of cancers. However, the correlation between NDRG2 expression and the prognosis of solid tumor remains to be elucidated because of small sample sizes and inconsistent results in previous studies. In the present study, we conducted a systematic review and meta-analysis to explore the prognostic significance of NDRG2 in human solid tumors.

Methods: PubMed, Web of Science, Embase, Chinese National Knowledge Infrastructure, and WanFang databases (up to April 2020) were searched for relevant studies that evaluated the impact of NDRG2 on clinical outcomes, including overall survival (OS), and disease-free survival (DFS), in solid tumors. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled to assess the association between NDRG2 expression and the survival of patients with solid tumors. Odds ratios (ORs) with 95% CIs were pooled to estimate the correlation between NDRG2 expression and clinicopathologic characteristics in the patients.

Results: A total of 13 eligible studies with 1980 patients were included in this meta-analysis. Low NDRG2 expression was significantly associated with poor OS (HR = 1.96, 95% CI: 1.60-2.40, P < .001) and DFS (HR = 2.70, 95% CI: 1.42-5.13, P = .002) in solid tumor. Furthermore, low NDRG2 expression was related to some phenotypes of tumor aggressiveness, such as clinical stage (OR = 3.21, 95% CI: 1.96-5.26, P < .001), lymph node metastasis (OR = 2.14, 95% CI: 1.49-3.07, P < .001), and degree of differentiation (OR = 0.60, 95% CI: 0.45-0.81, P = .001).

Conclusions: NDRG2 may be a meaningful biomarker of poor prognosis and a potential therapeutic target for human solid tumors.

Citing Articles

Low NDRG2, regulated by the MYC/MIZ-1 complex and methylation, predicts poor outcomes in DLBCL patients.

Wu S, Zhang J, Chen S, Zhou X, Liu Y, Hua H Ann Hematol. 2024; 103(8):2877-2892.

PMID: 38842567 DOI: 10.1007/s00277-024-05829-2.

Untargeted GC-MS-Based Metabolomics for Early Detection of Colorectal Cancer.

Zhu G, Wang Y, Wang W, Shang F, Pei B, Zhao Y Front Oncol. 2021; 11:729512.

PMID: 34804922 PMC: 8599589. DOI: 10.3389/fonc.2021.729512.

N-myc Downstream-Regulated Gene 2 (NDRG2) Function as a Positive Regulator of Apoptosis: A New Insight into NDRG2 as a Tumor Suppressor.

Kim G, Lim S, Kim K Cells. 2021; 10(10).

PMID: 34685629 PMC: 8534062. DOI: 10.3390/cells10102649.

References

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Furuta H, Kondo Y, Nakahata S, Hamasaki M, Sakoda S, Morishita K . NDRG2 is a candidate tumor-suppressor for oral squamous-cell carcinoma. Biochem Biophys Res Commun. 2010; 391(4):1785-91. DOI: 10.1016/j.bbrc.2009.12.156. View

Liang Z, Kang K, Yoon S, Huang S, Lim J, Kim J . NDRG2 is involved in the oncogenic properties of renal cell carcinoma and its loss is a novel independent poor prognostic factor after nephrectomy. Ann Surg Oncol. 2012; 19(8):2763-72. DOI: 10.1245/s10434-011-2204-3. View

Shon S, Kim A, Kim J, Kim K, Yang Y, Lim J . Bone morphogenetic protein-4 induced by NDRG2 expression inhibits MMP-9 activity in breast cancer cells. Biochem Biophys Res Commun. 2009; 385(2):198-203. DOI: 10.1016/j.bbrc.2009.05.038. View

Hu W, Yang Y, Fan C, Ma Z, Deng C, Li T . Clinical and pathological significance of N-Myc downstream-regulated gene 2 (NDRG2) in diverse human cancers. Apoptosis. 2016; 21(6):675-82. DOI: 10.1007/s10495-016-1244-3. View

Chen W, Peng J, Ou Q, Wen Y, Jiang W, Deng Y . Expression of NDRG2 in Human Colorectal Cancer and its Association with Prognosis. J Cancer. 2019; 10(15):3373-3380. PMC: 6603412. DOI: 10.7150/jca.31382. View

Yang C, Zheng X, Ye K, Ge H, Sun Y, Lu Y . NDRG2 suppresses proliferation, migration, invasion and epithelial-mesenchymal transition of esophageal cancer cells through regulating the AKT/XIAP signaling pathway. Int J Biochem Cell Biol. 2018; 99:43-51. DOI: 10.1016/j.biocel.2018.03.003. View

Godeke J, Luxenburger E, Trippel F, Becker K, Haberle B, Muller-Hocker J . Low expression of N-myc downstream-regulated gene 2 (NDRG2) correlates with poor prognosis in hepatoblastoma. Hepatol Int. 2015; 10(2):370-6. DOI: 10.1007/s12072-015-9686-1. View

Yong H, Koh M, Moon A . The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer. Expert Opin Investig Drugs. 2009; 18(12):1893-905. DOI: 10.1517/13543780903321490. View

10.

Liu N, Wang L, Liu X, Yang Q, Zhang J, Zhang W . Promoter methylation, mutation, and genomic deletion are involved in the decreased NDRG2 expression levels in several cancer cell lines. Biochem Biophys Res Commun. 2007; 358(1):164-9. DOI: 10.1016/j.bbrc.2007.04.089. View

11.

Shen L, Qu X, Li H, Xu C, Wei M, Wang Q . NDRG2 facilitates colorectal cancer differentiation through the regulation of Skp2-p21/p27 axis. Oncogene. 2018; 37(13):1759-1774. PMC: 5874257. DOI: 10.1038/s41388-017-0118-7. View

12.

Wang H, Wang W, Wang X, Cai K, Wu H, Ju Q . Reduced N-Myc downstream-regulated gene 2 expression is associated with CD24 upregulation and poor prognosis in patients with lung adenocarcinoma. Med Oncol. 2012; 29(5):3162-8. DOI: 10.1007/s12032-012-0231-y. View

13.

Guo Y, Li X, Sun X, Wang J, Yang X, Zhou X . Combined Aberrant Expression of NDRG2 and LDHA Predicts Hepatocellular Carcinoma Prognosis and Mediates the Anti-tumor Effect of Gemcitabine. Int J Biol Sci. 2019; 15(9):1771-1786. PMC: 6743297. DOI: 10.7150/ijbs.35094. View

14.

Yu M, Hao B, Zhan Y, Luo G . Krüppel-like factor 4 expression in solid tumor prognosis: A meta-analysis. Clin Chim Acta. 2018; 485:50-59. DOI: 10.1016/j.cca.2018.06.030. View

15.

Park Y, Shon S, Kim A, Kim K, Yang Y, Cho D . SOCS1 induced by NDRG2 expression negatively regulates STAT3 activation in breast cancer cells. Biochem Biophys Res Commun. 2007; 363(2):361-7. DOI: 10.1016/j.bbrc.2007.08.195. View

16.

Ma J, Liu W, Guo H, Li S, Cao W, Du X . N-myc downstream-regulated gene 2 expression is associated with glucose transport and correlated with prognosis in breast carcinoma. Breast Cancer Res. 2014; 16(2):R27. PMC: 4053222. DOI: 10.1186/bcr3628. View

17.

Li Y, Yang J, Li S, Zhang J, Zheng J, Hou W . N-myc downstream-regulated gene 2, a novel estrogen-targeted gene, is involved in the regulation of Na+/K+-ATPase. J Biol Chem. 2011; 286(37):32289-99. PMC: 3173200. DOI: 10.1074/jbc.M111.247825. View

18.

Ren G, Tang L, Yang A, Jiang W, Huang Y . Prognostic impact of NDRG2 and NDRG3 in prostate cancer patients undergoing radical prostatectomy. Histol Histopathol. 2013; 29(4):535-42. DOI: 10.14670/HH-29.10.535. View

19.

Duff D, Long A . Roles for RACK1 in cancer cell migration and invasion. Cell Signal. 2017; 35:250-255. DOI: 10.1016/j.cellsig.2017.03.005. View

20.

Kim Y, Yoon S, Kim J, Choi S, Lim J, Kim J . NDRG2 suppresses cell proliferation through down-regulation of AP-1 activity in human colon carcinoma cells. Int J Cancer. 2008; 124(1):7-15. DOI: 10.1002/ijc.23945. View